Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1

Conditions

Glioblastoma 4Brain Neoplasms 2Oligodendroglioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 163Radiosurgery 129Radiotherapy 107Bevacizumab 98Magnetic Resonance Spectroscopy 75Carboplatin 48Surgical Procedures, Operative 35pembrolizumab 34Radiation 34Etoposide 34Nivolumab 33Irinotecan 33Cyclophosphamide 33Erlotinib Hydrochloride 31Carmustine 28Trastuzumab 25Lomustine 25Cisplatin 25Ipilimumab 24Filgrastim 23Mental Status and Dementia Tests 21Magnetic Resonance Imaging 21Aminolevulinic Acid 21Vincristine 20Surveys and Questionnaires 19Capecitabine 19Topotecan 18Specimen Handling 18Pemetrexed 18Radiotherapy, Intensity-Modulated 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Brain Neoplasms × tislelizumab × CNS × Clear all
NCT04507217 2023-05-25

Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC

Sun Yat-sen University

Phase 2 Completed
36 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05207904 2022-01-26

Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases

Sun Yat-sen University

Phase 2 Unknown
41 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡